At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 246 target
Drug / intervention
CM512biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Atopic Dermatitis Patients.
In Brief
A Phase 2 clinical trial evaluating CM512 for Atopic Dermatitis (AD). Currently recruiting, targeting 246 participants across 1 site.
Detailed Summary
This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis (AD)
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
202620272028
First PostedNov 2025
Enrollment StartDec 2025
TodayJul 2026
Primary CompletionDec 2027
First PostedNov 17, 2025
Enrollment StartDec 1, 2025
Primary CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 7 months agoPrimary completion in 1.4 years
Interventions
CM512biological
CM512 subcutaneous injection